Leerink Partners Begins Coverage on Metsera (NASDAQ:MTSR)

Key Points

• Leerink Partners has initiated coverage on Metsera (NASDAQ:MTSR) with an "outperform" rating and a price target of $77.00, indicating a potential upside of 119.37% from the current stock price.
• Despite the positive outlook from Leerink, Wall Street Zen has downgraded Metsera from a "hold" to a "sell" rating, highlighting mixed analyst opinions on the stock.
• Metsera is a clinical stage biopharmaceutical company focused on developing hormone analog peptides for obesity and related conditions, with several products in its pipeline including MET-097i, MET-233, and MET-224o.

Leerink Partners began coverage on shares of Metsera (NASDAQ:MTSR - Get Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The firm set an "outperform" rating and a $77.00 price target on the stock. Leerink Partners' price target would indicate a potential upside of 115.87% from the stock's current price.

A number of other equities research analysts have also issued reports on the company. Bank of America lifted their target price on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Wells Fargo & Company began coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Wall Street Zen lowered Metsera from a "hold" rating to a "sell" rating in a research report on Sunday, September 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Finally, Guggenheim lifted their target price on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, Metsera has an average rating of "Buy" and an average price target of $63.50.

Metsera Trading Down 4.2%

Shares of NASDAQ:MTSR traded down $1.58 during trading on Tuesday, hitting $35.67. 1,611,155 shares of the company's stock traded hands, compared to its average volume of 1,041,620. Metsera has a 52 week low of $12.30 and a 52 week high of $47.40. The company has a 50-day moving average price of $35.37 and a 200-day moving average price of $28.81.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its position in shares of Metsera by 45.5% during the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock worth $27,000 after purchasing an additional 296 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Metsera by 100.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock worth $46,000 after purchasing an additional 800 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in shares of Metsera by 32.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company's stock worth $122,000 after purchasing an additional 1,056 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Metsera by 7.9% during the 2nd quarter. Prudential Financial Inc. now owns 16,070 shares of the company's stock worth $457,000 after purchasing an additional 1,170 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Metsera by 25.0% during the 2nd quarter. New York State Common Retirement Fund now owns 6,000 shares of the company's stock worth $171,000 after purchasing an additional 1,200 shares during the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.